Paper Details

  1. Home
  2. Paper Details

[Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis].

Author: LakatosLászló, LakatosPéter László

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

5-aminosalicylate (5-ASA) agents are the mainstay treatment for ulcerative colitis (UC). Several oral 5-ASA agents are available, including azo-bond pro-drugs like sulfasalazine, olsalazine, and balsalazide, as well as delayed- and controlled-release forms of mesalazine. Achieving good compliance with oral therapy is crucial for its effectiveness, but frequent daily dosing and a high pill burden can negatively impact compliance. Poor adherence poses a significant barrier to successfully managing UC. Newly developed once-daily mesalazine formulations, including the multi-matrix delivery system and mesalazine granules, have been proven effective in inducing and maintaining remission in mild-to-moderate UC. These formulations have a good safety profile comparable to other oral mesalazine formulations and offer the advantage of a lower pill burden. This may contribute to increased long-term compliance, treatment success in clinical practice, and potentially reduce the risk of UC-associated colon cancers. This systematic review summarizes the available literature on the short- and medium-term efficacy and safety of these new once-daily mesalazine formulations.
Paper Details　
Original Abstract of the Article :
5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents is commercially available, including azo-bond pro-drugs such as sulfasalazine, olsalazine and balsalazide, and delayed- and controlled-release forms of mesalazine. In addition, th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1556/OH.2009.28555

データ提供：米国国立医学図書館（NLM）

5-Aminosalicylic Acid for Ulcerative Colitis: A New Oasis in Treatment

The journey of finding effective treatments for ulcerative colitis (UC) can be a challenging one. This research explores the efficacy and safety of new, once-daily formulations of 5-aminosalicylic acid (5-ASA) in treating UC, offering a potential solution for improving patient compliance and long-term treatment outcomes. The study highlights the importance of finding effective and convenient treatment options for patients with chronic inflammatory bowel diseases.

Navigating the Desert of UC Treatment

The study reviewed the available literature on the short- and medium-term efficacy and safety of new, once-daily formulations of mesalazine, a type of 5-ASA medication. The findings indicated that these new formulations were effective in inducing and maintaining remission in patients with mild-to-moderate UC, with a good safety profile comparable to other oral mesalazine formulations. This research, like a caravan of explorers discovering new routes across the desert, offers a promising new approach to treating UC.

The Impact of New Treatment Options on Patient Care

This research highlights the potential benefits of once-daily formulations of 5-ASA medications for UC patients, offering a more convenient and potentially more effective treatment option. The study emphasizes the importance of finding treatments that improve patient compliance and lead to better long-term outcomes. This research, like a well-placed oasis providing respite from the harsh desert conditions, provides hope for patients with UC.

Dr.Camel's Conclusion

The study highlights the promise of new once-daily formulations of 5-ASA medications for treating UC. This research, like a caravan of camels carrying precious resources across the desert, provides a valuable new option for patients seeking to effectively manage their UC.

Date :
  1. Date Completed 2009-04-10
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

19228568

DOI: Digital Object Identifier

10.1556/OH.2009.28555

Related Literature

Article Analysis
・Effects of balsalazide
SNS
PICO Info
in preparation
Languages

Hungarian

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.